Klin Farmakol Farm. 2015;29(1):39-42

A fixed combination Cyclo 3 Fort in the treatment of CVI

Jiří Slíva
Ústavy farmakologie 2. a 3. LF UK, Praha

Cyclo 3 Fort fixed combination in the treatment of chronic venous insufficiency

Venoactive drugs are a popular group of drugs which have been mostly used in the treatment of chronic venous insufficiency, along

with other therapeutic approaches, especially compressive treatment. The article focuses on a review of available data on the Cyclo 3

Fort formulation, both from preclinical (i.e. especially documentation of the mechanism of action) and clinical point of view.

Keywords: chronic venous insufficiency, CVI, venoactive drugs, Ruscus, hesperidin, ascorbic acid, Cyclo 3 Fort

Published: March 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slíva J. A fixed combination Cyclo 3 Fort in the treatment of CVI. Klin Farmakol Farm. 2015;29(1):39-42.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Thebault JJ. [Effects of a phlebotonic agent]. Fortschr.Med 1983; 101: 1206-1212. Go to PubMed...
    2. Domange JR, Bougaret S, Yubero L. Pharmacological studies of Cyclo 3 Fort and its constituents (Ruscus extract, hesperidin methyl chalcone, ascorbic acid): an up to date review. Clinical Hemorheology 1994; 14: S7-S13.
    3. Marcelon G, Verbeuren TJ, Lauressergues H, Vanhoutte PM. Effect of Ruscus aculeatus on isolated canine cutaneous veins. Gen. Pharmacol 1983; 14: 103-106. Go to original source... Go to PubMed...
    4. Bouskela E, Cyrino FZ, Marcelon G. Effects of Ruscus extract on the internal diameter of arterioles and venules of the hamster cheek pouch microcirculation. J Cardiovasc. Pharmacol 1993; 22: 221-224. Go to original source... Go to PubMed...
    5. Svensjo E, Bouskela E, Cyrino FZ, Bougaret S. Antipermeability effects of Cyclo 3 Fort in hamsters with moderate diabetes. Clin Hemorheol.Microcirc. 1997; 17: 385-388. Go to PubMed...
    6. Bouskela E, Cyrino FZ, Marcelon G. Inhibitory effect of the Ruscus extract and of the flavonoid hesperidine methylchalcone onincreased microvascular permeability induced by various agents in the hamster cheek pouch. J Cardiovasc. Pharmacol 1993; 22: 225-230. Go to original source... Go to PubMed...
    7. Marcelon G, Vanhoutte PM. Venotonic effect of Ruscus under variable temperature conditions in vitro. Phlebology 1988; 3: 51-54.
    8. Rubanyi G, Marcelon G, Vanhoutte PM. Effect of temperature on the responsiveness of cutaneous veins to the extract of Ruscus aculeatus. Gen. Pharmacol 1984; 15: 431-434. Go to original source... Go to PubMed...
    9. Bouaziz N, Michiels C, Janssens D, et al. Effect of Ruscus extract and hesperidin methylchalcone on hypoxia-induced activation of endothelial cells. Int.Angiol. 1999; 18: 306-312. Go to PubMed...
    10. Janssens D, Delaive E, Houbion A, Eliaers F, Remacle J, Michiels C. Effect of venotropic drugs on the respiratory activity of isolated mitochondria and in endothelial cells. Br.J Pharmacol 2000; 130: 1513-1524. Go to original source... Go to PubMed...
    11. Bouskela E, Donyo KA. Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia/reperfusion in the hamster cheek pouch. Angiology 1997; 48: 391-399. Go to original source... Go to PubMed...
    12. Geroulakos G, Nicolaides AN. Controlled studies of Daflon 500 mg in chronic venous insufficiency. Angiology 1994; 45: 549-553. Go to PubMed...
    13. Jean T, Bodinier MC. Mediators involved in inflammation: effects of Daflon 500 mg on their release. Angiology 1994; 45: 554-559. Go to PubMed...
    14. Labrid C. Pharmacologic properties of Daflon 500 mg. Angiology 1994; 45: 524-530. Go to PubMed...
    15. McGregor L, Bellangeon M, Chignier E, Lerond L, Rousselle C, McGregor JL. Effect of a micronized purified flavonoid fraction on in vivo platelet functions in the rat. Thromb. Res 1999; 94: 235-240. Go to original source... Go to PubMed...
    16. Allegra C, Bartolo M, Jr., Carioti B, Cassiani D. An original microhaemorheological approach to the pharmacological effects of Daflon 500 mg in severe chronic venous insufficiency. Int J. Microcirc. Clin Exp 1995; 15 Suppl 1: 50-54. Go to original source... Go to PubMed...
    17. Shoab SS, Porter J, Scurr JH, Coleridge-Smith PD. Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease - a prospective study. Eur. J. Vasc. Endovasc. Surg. 1999; 17: 313-318. Go to original source... Go to PubMed...
    18. Galati EM, Trovato A, Kirjavainen S, Forestieri AM, Rossitto A, Monforte MT. Biological effects of hesperidin, a Citrus flavonoid. (Note III): antihypertensive and diuretic activity in rat. Farmaco 1996; 51: 219-221. Go to original source... Go to PubMed...
    19. Monforte MT, Trovato A, Kirjavainen S, Forestieri AM, Galati EM, Lo Curto RB. Biological effects of hesperidin, a Citrus flavonoid. (note II): hypolipidemic activity on experimental hypercholesterolemia in rat. Farmaco 1995; 50: 595-599. Go to PubMed...
    20. Ohtsuki K, Abe A, Mitsuzuwi H, et al. Effects of long-term administration of hesperidin and glucosyl hesperidin to spontaneously hypertensive rats. J.Nutr.Sci Vitaminol. (Tokyo) 2002; 48: 420-422. Go to original source... Go to PubMed...
    21. Park YB, Do KM, Bok SH, Lee MK, Jeong TS, Choi MS. Interactive effect of hesperidin and vitamin E supplements on cholesterol metabolism in high cholesterol-fed rats. Int J. Vitam. Nutr. Res 2001; 71: 36-44. Go to original source... Go to PubMed...
    22. Sakata K, Hirose Y, Qiao Z, Tanaka T, Mori H. Inhibition of inducible isoforms of cyclooxygenase and nitric oxide synthase by flavonoid hesperidin in mouse macrophage cell line. Cancer Lett. 2003; 199: 139-145. Go to original source... Go to PubMed...
    23. Vanscheidt W, Jost V, Wolna P, et al. Efficacy and safety of a Butcher's broom preparation (Ruscus aculeatus L. extract) compared to placebo in patients suffering from chronic venous insufficiency. Arzneimittelforschung. 2002; 52: 243-250. Go to original source...
    24. Beltramino R, Penenory A, Buceta AM. An open-label, randomised multicentre study comparing the efficacy and safety of CYCLO 3 FORT versus hydroxyethyl rutoside in chronic venous lymphatic insufficiency. Int.Angiol. 1999; 18: 337-342. Go to original source... Go to PubMed...
    25. Ruscus aculeatus (butcher's broom). Monograph. Altern. Med Rev. 2001; 6: 608-612.
    26. Boyle P, Diehm C, Robertson C. Meta-analysis of clinical trials of Cyclo 3 Fort in the treatment of chronic venous insufficiency. Int. Angiol. 2003; 22: 250-262. Go to PubMed...
    27. Aguilar Peralta GR, Arevalo GJ, Llamas Macias FJ, Navarro Ceja VH, Mendoza Cisneros SA, Martinez Macias CG. Clinical and capillaroscopic evaluation in the treatment of chronic venous insufficiency with Ruscus aculeatus, hesperidin methylchalcone and ascorbic acid in venous insufficiency treatment of ambulatory patients. Int.Angiol. 2007; 26: 378-384. Go to PubMed...
    28. Allaert FA, Hugue C, Cazaubon M, Renaudin JM, Clavel T, Escourrou P. Correlation between improvement in functional signs and plethysmographic parameters during venoactive treatment (Cyclo 3 Fort). Int.Angiol. 2011; 30: 272-277. Go to PubMed...
    29. Guex JJ, Enriquez Vega DM, Avril L, Boussetta S, Taieb C. Assessment of quality of life in Mexican patients suffering from chronic venous disorder - impact of oral Ruscus aculeatus-hesperidin-methyl-chalcone-ascorbic acid treatment -, QUALITY Study'. Phlebology. 2009; 24: 157-165. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.